EBPC is primarily researched for its potential in cancer therapy due to its ability to inhibit tumor growth. It has shown promise in preclinical studies by targeting specific cellular pathways involved in cancer progression. The compound is being explored for its efficacy in combination with other chemotherapeutic agents to enhance treatment outcomes. Additionally, EBPC is investigated for its role in reducing drug resistance in certain cancer types, making it a candidate for improving long-term therapeutic strategies. Its application extends to studying its effects on cell cycle regulation and apoptosis, which are critical in understanding and developing new cancer treatments.